BidaskClub lowered shares of Lantheus (NASDAQ:LNTH) from a strong-buy rating to a buy rating in a report published on Tuesday, BidAskClub reports.

A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Lantheus from a buy rating to a hold rating in a report on Wednesday, April 24th. TheStreet raised shares of Lantheus from a c+ rating to a b rating in a report on Monday, March 4th. Finally, ValuEngine raised shares of Lantheus from a hold rating to a buy rating in a report on Wednesday, February 20th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $23.33.

Shares of Lantheus stock opened at $25.24 on Tuesday. The company has a debt-to-equity ratio of 3.16, a current ratio of 4.57 and a quick ratio of 3.82. The company has a market capitalization of $982.92 million, a P/E ratio of 26.85, a P/E/G ratio of 1.90 and a beta of 1.46. Lantheus has a fifty-two week low of $12.59 and a fifty-two week high of $26.40.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The business had revenue of $86.51 million during the quarter, compared to analyst estimates of $86.80 million. Lantheus had a net margin of 12.17% and a return on equity of 59.57%. Equities analysts predict that Lantheus will post 1.11 earnings per share for the current fiscal year.

In other Lantheus news, CEO Mary Anne Heino sold 15,799 shares of Lantheus stock in a transaction on Friday, April 12th. The shares were sold at an average price of $25.40, for a total transaction of $401,294.60. Following the completion of the sale, the chief executive officer now owns 684,402 shares of the company’s stock, valued at approximately $17,383,810.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sam R. Leno sold 3,950 shares of Lantheus stock in a transaction on Friday, June 7th. The stock was sold at an average price of $25.33, for a total transaction of $100,053.50. Following the sale, the director now directly owns 49,580 shares of the company’s stock, valued at approximately $1,255,861.40. The disclosure for this sale can be found here. Insiders have sold a total of 143,297 shares of company stock valued at $3,519,291 in the last ninety days. Company insiders own 2.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlueMountain Capital Management LLC grew its holdings in Lantheus by 87.5% during the 1st quarter. BlueMountain Capital Management LLC now owns 21,429 shares of the medical equipment provider’s stock worth $525,000 after acquiring an additional 10,003 shares during the period. Jane Street Group LLC acquired a new stake in Lantheus during the 1st quarter worth $378,000. RMB Capital Management LLC acquired a new stake in Lantheus during the 1st quarter worth $333,000. Man Group plc grew its holdings in Lantheus by 29.9% during the 1st quarter. Man Group plc now owns 155,393 shares of the medical equipment provider’s stock worth $3,804,000 after acquiring an additional 35,772 shares during the period. Finally, C M Bidwell & Associates Ltd. bought a new position in shares of Lantheus during the first quarter worth $45,000. 92.56% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Story: Diluted Earnings Per Share

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.